Ticagrelor - AstraZeneca

Drug Profile

Ticagrelor - AstraZeneca

Alternative Names: AR-C-126532; AZD-6140; Brilinta; Brilique

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; The Medicines Company; Uppsala University; Vanderbilt University
  • Class Antithrombotics; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Cardiovascular disorders; Stroke
  • Phase II Abdominal aortic aneurysm; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 14 May 2018 AstraZeneca plans the phase III HESTIA3 trial for Sickle cell disease (IN children, In adolescents) in Belgium, Brazil, Canada, Egypt, Ghana, Greece, India, Italy, Kenya, Lebanon, Saudi Arabia, South Africa, Spain, Tanzania, Turkey, Uganda, United Kingdom and USA (PO) (EudraCT2017-002421-38)
  • 11 Mar 2018 Initial efficacy and adverse events data from the phase III TREAT trial in Acute coronary syndromes released by AstraZeneca
  • 07 Feb 2018 Pre-specified sub-analysis of efficacy and adverse events data from a phase III PEGASUS-TIMI 54 trial in Acute coronary syndromes released by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top